产品
编 号：F385571
分子式：C14H26O2
分子量：226.36
分子式：C14H26O2
分子量：226.36
产品类型
规格
价格
是否有货
100mg
询价
询价
结构图
CAS No: 544-64-9
产品详情
生物活性：
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.
体内研究：
Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice.Animal Model:C57BL/6 mice at 5 weeks.
Dosage:0.2, 2 mg/kg
Administration:IP every 24 h for 4 days.
Result:Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.
体外研究：
Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation.
Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.
体内研究：
Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice.Animal Model:C57BL/6 mice at 5 weeks.
Dosage:0.2, 2 mg/kg
Administration:IP every 24 h for 4 days.
Result:Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.
体外研究：
Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备